After the introduction of intravitreal anti-VEGF (vascular endothelial growth factor) as therapy for exudative AMD some reports of antiangiogenic injections for CNV of other causes than AMD [8–10] and in younger populations [11] have been published. This evidence concerns the gene VEGFA and age-related macular degeneration.